Sridhar Prasad

San Diego, CA

Dr. Prasad has been the core member of multiple drug discovery teams that discovered drug and drug candidates that are currently at various stages of preclinical and clinical development, including MK-4965. He was the lead crystallographer and core member of the team that discovered NESINA a drug to treat type II diabetes, first drug to be discovered using structure-based methods at Syrrx (Takeda). He designed, built and implemented fragment based crystallography screening technology platforms at Syrrx (Takeda), Merck and Metabasis. He has co-authored over 45 peer reviewed research articles, holds 6 US and international patents. He serves on the editorial board of Current Protein and Peptide Science (CPPS). Dr. Prasad obtained his Ph.D., from Indian Institute of Science, Bangalore, India and post-doctoral training at University of Minnesota Medical School and the Scripps Research Institute, La Jolla, California, where he subsequently grew to the ranks of Assistant Professor.

  • Work
    • DRUG DISCOVERY AND DEVELOPMENT
  • Education
    • PHD